此外，不少研究指出，及早发现、及时诊断乳腺癌不同临床亚型，并针对性地为个体制定精准治疗方 案，选择安全有效的治疗手段，能够显著延长乳腺癌患者生存时间并提高生活质量。殷咏梅教授补充 道，随着越来越多创新抗肿瘤药物的出现，如何为患者制定个体化精准治疗方案，以提升患者获益，成 为关注重点。"而由于乳腺癌异质性强，多学科诊疗模式应贯穿乳腺癌治疗全过程，基于循证医学的多 学科团队、综合最佳证据、专家经验和患者意愿，使患者诊治过程个性化、精准化；同时也可以优化医 疗资源使用，提高诊疗的合理性，减少偏倚，最终通过临床诊疗决策的转变，乳腺癌患者有望'活得更 长、活得更好'，实现生命长度与宽度的双重提升。" "但现实问题是，一旦发生耐药，患者后续的治疗选择就会变得非常有限。"殷咏梅教授解释说，乳腺癌 患内分泌治疗的耐药，绝大多数是和PAM通路的激活，尤其是像PIK3CA突变，AKT突变等这条信号通 路上的一些基因突变或者激活有关。"过去，内分泌治疗的一些靶向药物在没有纳入医保钱，患者每个 月的花费可能要接近3万元，这些费用对于绝大多数患者而言都是一笔难以支付的巨大开支。此次包含 靶向PAM通路创新药物在内的一批乳腺癌领域的创新 ...

Core Viewpoint - The chemotherapy drug market in China is experiencing growth due to increasing cancer patient numbers and rising consumer spending, despite competition from targeted therapies. Chemotherapy drugs remain dominant due to their stable efficacy, broad anti-cancer properties, and relatively low prices [1][4][5]. Group 1: Industry Overview - Chemotherapy drugs are a crucial method for cancer treatment, classified into various types such as alkylating agents, antimetabolites, and plant-derived anticancer drugs [2][3]. - The demand for chemotherapy drugs in China is projected to reach 3.858 billion units with a market size of 135.59 billion yuan in 2024, led by plant alkaloids and antimetabolites [5][6]. - The global chemotherapy drug market is expected to grow from 33.53 billion USD in 2024 to 36.84 billion USD in 2025, with the Asia-Pacific region holding a significant share [4][5]. Group 2: Market Dynamics - The Chinese chemotherapy drug market is characterized by a dual driving force of strong demand for certain drug types while facing pressure from generics and targeted therapies [5][10]. - The production of chemotherapy drugs in China is anticipated to increase to 3.432 billion units by 2025, reflecting a growth trend in domestic manufacturing capabilities [6][10]. - The competitive landscape is intensifying with local companies like Heng Rui Medicine and Qilu Pharmaceutical making significant strides in both generic and innovative drug development [10][11]. Group 3: Regulatory Environment - The Chinese government has implemented supportive policies to encourage the development of innovative cancer treatment drugs, providing a favorable environment for industry growth [8][9]. - The industry is witnessing accelerated drug approval processes and procurement policies that favor local manufacturers, enhancing competition [10][11]. Group 4: Future Trends - The chemotherapy drug sector is expected to evolve towards precision medicine, with advancements in targeted therapies and combination treatments [11]. - Innovations in drug delivery systems, such as nanotechnology, are anticipated to enhance treatment efficacy and patient outcomes [11].